DURATION OF ACTIVITY
June 20, 2022 through June 19, 2024
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedicusCME and Comprehensive Psychiatric Resources, Inc. MedicusCME is accredited by the ACCME to provide continuing medical education for physicians.
MedicusCME designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Schizophrenia is a challenging condition to treat, often with lifelong consequences. A number of nutritional and integrative approaches appear to hold some promise in reducing symptoms, typically with lower risks for side effects. This course reviews some of the history and the research around integrative approaches to schizophrenia treatment.
- Describe the background, history and efficacy of current medication treatments for schizophrenia
- Review and assess the history of integrative or “orthomolecular” mental health care
- Identify and assess the potential of integrative schizophrenia treatments, including pregnenolone, omega-3 fatty acids, niacin, vitamin C, vitamin D, vitamin B6, zinc, folate, vitamin B12, minocycline, cannabidiol, N-acetylcysteine, glycine, taurine and L-theanine
- Elucidate the relationship between inflammation, causes of inflammation and schizophrenia, including infections, celiac disease, diet and gut flora disturbances
HOW TO CLAIM CREDIT
In order to receive AMA PRA Category 1 credit™, participants must do the following:
- Read the learning objectives and faculty disclosures
- Participate in the activity, review course content and learning strategies, resources and support materials provided
- Complete the post-test and activity evaluation
- Achieve a score of 80% or higher on the post-test
FACULTY CONTENT EXPERT
James Greenblatt, MD
Chief Medical Officer and Vice President of Medical Services
Walden Behavioral Care, Waltham, Massachusetts
Assistant Clinical Professor of Psychiatry
Tufts University School of Medicine
DISCLOSURE OF FINANCIAL RELATIONSHIPS
MedicusCME requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to MedicusCME policy.
The faculty reported the following relevant financial relationships with Accreditation Council for Continuing Medical Education (ACCME)-defined ineligible entities related to the educational content of this CE activity.
James Greenblatt, MD has disclosed a financial relationship with Pure Encapsulations and Jaymac Pharmaceuticals for his role as consultant.
All other planners and faculty, including MedicusCME planners and managers, have no relevant financial relationships with ineligible companies to disclose. Any relevant financial relationships listed for planners or content contributors have been mitigated according to MedicusCME policies.
This activity is not supported by funds from an ACCME-defined ineligible company.
HIPPA COMPLIANCE ATTESTATION
In accordance with the Health Insurance Portability and Accountability Act (HIPAA), this educational activity, especially when utilizing patient cases for learning demonstration, will not include individually identifiable health information.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.